MARKET

NOVN

NOVN

Novan Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.580
+0.050
+1.98%
After Hours: 2.510 -0.07 -2.71% 17:04 05/27 EDT
OPEN
2.670
PREV CLOSE
2.530
HIGH
2.670
LOW
2.520
VOLUME
69.13K
TURNOVER
0
52 WEEK HIGH
20.74
52 WEEK LOW
2.240
MARKET CAP
49.47M
P/E (TTM)
-1.3729
1D
5D
1M
3M
1Y
5Y
NOVN: First EPI Sales
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ:NOVN) reported first quarter financial and operational results in a press release and the filing of Form 10-Q . A confer...
Zacks Small Cap Research · 4d ago
38 Stocks Moving In Thursday's Mid-Day Session
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares climbed 34.6% to $4.1993 after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia.
Benzinga · 05/19 16:31
Novan To Present Berdazimer Gel, 10.3% (SB206) Clinical Data At Annual Meeting Of The Society For Investigative Dermatology
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology – Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical
Benzinga · 05/19 13:13
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum – – Curre...
GlobeNewswire · 05/19 13:05
Novan: Q1 Earnings Insights
  Novan (NASDAQ:NOVN) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/16 11:34
BRIEF-Novan Reports Q1 Loss Of 71 Cents Per Share
reuters.com · 05/16 10:39
Novan Q1 EPS $(0.71) Misses $(0.60) Estimate, Sales $1.90M Beat $1.35M Estimate
Novan (NASDAQ:NOVN) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.60) by 18.33 percent. This is a 1083.33 percent decrease over losses of $(0.06) per share from the
Benzinga · 05/16 10:34
Novan GAAP EPS of -$0.71, revenue of $1.9M
Novan press release (NASDAQ:NOVN): Q1 GAAP EPS of -$0.71. Revenue of $1.9M (+137.5% Y/Y). As of March 31, 2022, Novan had a total cash and cash equivalents balance of $35.5
Seekingalpha · 05/16 10:32
More
No Data
Learn about the latest financial forecast of NOVN. Analyze the recent business situations of Novan Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NOVN stock price target is 30.40 with a high estimate of 41.00 and a low estimate of 17.00.
High41.00
Average30.40
Low17.00
Current 2.580
EPS
Actual
Estimate
-0.57-0.43-0.28-0.14
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 48
Institutional Holdings: 3.07M
% Owned: 16.01%
Shares Outstanding: 19.17M
TypeInstitutionsShares
Increased
4
13.58K
New
14
1.00M
Decreased
6
16.96K
Sold Out
4
177.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.69%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/President/Chief Executive Officer/Director
Paula Stafford
Chief Financial Officer/Vice President - Finance/Controller/Secretary
John Gay
Other
Brian Johnson
Lead Director/Independent Director
W. Geer
Independent Director
James Bierman
Independent Director
Robert Keegan
Independent Director
John Palmour
Independent Director
A. Machelle Sanders
Independent Director
Steven Skolsky
No Data
No Data
About NOVN
Novan, Inc. is a late clinical-stage biotechnology company. The Company is focused on leveraging its nitric oxide (NO)-based technology platform, NITRICIL, to generate macromolecular new chemical entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases, and various other medical conditions. The Company has clinical-stage dermatology drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208) and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, a topical gel with antiviral properties, for the treatment of molluscum. The Company is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19 and is conducting in-vitro assessments targeting the reduction of viral burden and transmission. The Company is developing NVN4100, an antimicrobial indication for the adjacent companion animal health market.

Webull offers kinds of Novan Inc stock information, including NASDAQ:NOVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NOVN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NOVN stock methods without spending real money on the virtual paper trading platform.